Hanson Pharmaceuticals (03692): B7-H3 targeting antibody-drug conjugate HS-20093 for non-squamous non-small cell lung cancer was included as a breakthrough treatment by the State Drug Administration

Zhitong Finance App News, Hanson Pharmaceuticals (03692) announced that on April 17, 2025, the Group's self-developed B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 for injection was approved by the China National Drug Administration (NMPA) to be included as a breakthrough therapeutic drug. The proposed indication is for locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed or recurred after previous platinum-containing chemotherapy.

HS-20093 is a B7-H3 targeting ADC, formed by covalently linking an all-human anti-B7-H3 monoclonal antibody with a topoisomerase inhibitor (topoI) payload. Multiple clinical studies for the treatment of lung cancer, sarcoma, head and neck cancer, and other solid tumors are being carried out in China. The highest research stage is clinical phase III. On November 1, 2024, the indication HS-20093 for extensive small cell lung cancer (ES-SCLC) progressing after standard first-line treatment (platinum-containing dual-agent chemotherapy combined immunization) was included as a breakthrough treatment by NMPA. On February 25, 2025, HS-20093 was included in the NMPA as a breakthrough treatment for patients with osteosarcoma that progressed after at least second-line treatment.